1824 related articles for article (PubMed ID: 28029927)
1. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
Brown CE; Alizadeh D; Starr R; Weng L; Wagner JR; Naranjo A; Ostberg JR; Blanchard MS; Kilpatrick J; Simpson J; Kurien A; Priceman SJ; Wang X; Harshbarger TL; D'Apuzzo M; Ressler JA; Jensen MC; Barish ME; Chen M; Portnow J; Forman SJ; Badie B
N Engl J Med; 2016 Dec; 375(26):2561-9. PubMed ID: 28029927
[TBL] [Abstract][Full Text] [Related]
2. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
3. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
4. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
5. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
6. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
Bagley SJ; Logun M; Fraietta JA; Wang X; Desai AS; Bagley LJ; Nabavizadeh A; Jarocha D; Martins R; Maloney E; Lledo L; Stein C; Marshall A; Leskowitz R; Jadlowsky JK; Christensen S; Oner BS; Plesa G; Brennan A; Gonzalez V; Chen F; Sun Y; Gladney W; Barrett D; Nasrallah MP; Hwang WT; Ming GL; Song H; Siegel DL; June CH; Hexner EO; Binder ZA; O'Rourke DM
Nat Med; 2024 May; 30(5):1320-1329. PubMed ID: 38480922
[TBL] [Abstract][Full Text] [Related]
8. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
Vitanza NA; Johnson AJ; Wilson AL; Brown C; Yokoyama JK; Künkele A; Chang CA; Rawlings-Rhea S; Huang W; Seidel K; Albert CM; Pinto N; Gust J; Finn LS; Ojemann JG; Wright J; Orentas RJ; Baldwin M; Gardner RA; Jensen MC; Park JR
Nat Med; 2021 Sep; 27(9):1544-1552. PubMed ID: 34253928
[TBL] [Abstract][Full Text] [Related]
9. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
10. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
11. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
[TBL] [Abstract][Full Text] [Related]
12. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
[TBL] [Abstract][Full Text] [Related]
13. Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma.
Brown CE; Rodriguez A; Palmer J; Ostberg JR; Naranjo A; Wagner JR; Aguilar B; Starr R; Weng L; Synold TW; Tran V; Wang S; Reik A; D'Apuzzo M; Ressler JA; Zhou Y; Mendel M; Gregory PD; Holmes MC; Tang WW; Forman SJ; Jensen MC; Badie B
Neuro Oncol; 2022 Aug; 24(8):1318-1330. PubMed ID: 35100373
[TBL] [Abstract][Full Text] [Related]
14. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
15. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
[TBL] [Abstract][Full Text] [Related]
16. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
[TBL] [Abstract][Full Text] [Related]
17. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
[TBL] [Abstract][Full Text] [Related]
18. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.
Barish ME; Weng L; Awabdeh D; Zhai Y; Starr R; D'Apuzzo M; Rockne RC; Li H; Badie B; Forman SJ; Brown CE
Neoplasia; 2022 Aug; 30():100801. PubMed ID: 35550513
[TBL] [Abstract][Full Text] [Related]
19. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
[TBL] [Abstract][Full Text] [Related]
20. Targeting Glioblastoma with CAR T Cells.
Cancer Discov; 2017 Mar; 7(3):238-239. PubMed ID: 28108463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
